{
  "report_rows": [
    {
      "kpi": "Q2 2026 normalized FFO per share",
      "prediction": "BEAT",
      "answer": "pred ~$1.58 vs. cons $1.55",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.49B vs. cons $3.43B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 SHO same-store NOI growth",
      "prediction": "BEAT",
      "answer": "pred ~21.0% vs. cons 20.0%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Normalized FFO per share",
      "prediction": "BETTER",
      "answer": "guide ~$6.38 vs. cons $6.32 (FY2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "SHO same-store NOI growth",
      "prediction": "BETTER",
      "answer": "guide ~20.0% vs. cons 19.5% (FY2026 midpoint)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.4,
  "day1_confidence": "LOW",
  "day5_residual_pct": 2.3,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FY2026 FFO guide of ~$6.38 less predicted H1 FFO of ~$3.05 implies H2 FFO of ~$3.33 vs. cons ~$3.30; modest positive out-period revisions should support follow-through, though WELL's premium valuation limits upside.",
  "day5_confidence": "LOW"
}